PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.
Cell Death Differ. 2022 Apr 5. doi: 10.1038/s41418-022-00990-5. Online ahead of print.
Cell Death Differ. 2022.
PMID: 35383293